Early indications of finerenone’s beneficial impact on cardiac function in HF were observed in the phase II Mineralocorticoid Receptor Antagonist Tolerability Study (ARTS) trial (Table 1), a safety and tolerability study. This evidence concerns the gene NR3C2 and hydrops fetalis.